Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib and Trastuzumab with Neoadjuvant Chemotherapy for Early HER2-Positive Breast Cancer
NCT07635342Phase 2Recruiting
- Sponsor
- The Fourth Hospital of Hebei Medical University
- Start
- Apr 2024
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pyrotinib in breast cancer, sponsored by The Fourth Hospital of Hebei Medical University. Primary endpoint: Total Pathological Complete Response Rate at 24 weeks. Started Apr 2024; status: recruiting.
02
Drugs
pyrotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07635342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07635342.